A brief and feasible paper-based method to screen for neurocognitive impairment in HIV-infected patients: The NEU screen

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 5, 2013, Pages 585-592

  Muñoz Moreno, Jose A ^a,b   Prats, Anna ^a,b   Pérez Álvarez, Núria ^a,c   Fumaz, Carmina R ^a,b   Garolera, Maite ^d,e   Doval, Eduardo ^b   Negredo, Eugènia ^a,b   Ferrer, Maria J ^a,b   Clotet, Bonaventura ^a,b,f  

^a Lluita Contra la SIDA Foundation   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

^d HOSPITAL DE TERRASSA   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f Institut de Recerca de la SIDA IrsiCaixa   (Spain)

Author keywords

HIV infection; Neurocognitive impairment; Screening methods

Indexed keywords

ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COGNITIVE DEFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VERBAL BEHAVIOR;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-RETROVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84883348146     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31829e1408     Document Type: Article

References (59)

1. Schouten J, Cinque P, Gisslen M, et al. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS. 2011;25:561-575.
2. Tozzi V, Balestra P, Murri R, et al. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS. 2004;15:254-259.
3. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc. 2004;10:317-331.
4. Waldrop-Valverde D, Jones DL, Gould F, et al. Neurocognition, healthrelated reading literacy, and numeracy in medication management for HIV infection. AIDS Patient Care STDS. 2010;24:477-484.
5. Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21:706-713.
6. Sevigny JJ, Albert SM, McDermott MP, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol. 2007;64:97-102.
7. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-1799.
8. Muñoz-Moreno JA. Neurocognitive and motor disorders in HIV infection. Assessment and interventions. In: Plishe VN, ed. Research Focus on Cognitive Disorders. Hauppauge, NY: Nova Science Publishers, Inc; 2007, pp. 133-147.
9. Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis. 2013;56:1004-1017.
10. Valcour VG. Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools. Top Antivir Med. 2011;19: 175-180.
11. Letendre S, Ellis R, Deutsch R, et al. Correlates of Time-to-Loss-of- Viral-Response in CSF and Plasma in the CHARTER Cohort. Paper presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA. Abstract 430.
12. Muñoz-Moreno JA, Fumaz CR, Prats A, et al. Interruptions of antiretroviral therapy in HIV infection: are they detrimental to neurocognitive functioning? J Neurovirol. 2010;16:208-218.
13. Beck AT, Rush AJ, Shaw BF, et al. Cognitive Therapy of Depression. New York, NY: Guilford Press; 1979.
14. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1970.
15. Beck AT, Steer RA, Brown GK. Beck Depression Inventory: Manual BDI-II. New York, NY: Psychological Corporation; 1996.
16. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care. 1991;29:786-798.
17. The Psychological Corporation. Wechsler Adult Intelligence Scale - Third Edition (WAIS-III). San Antonio, TX: The Psychological Corporation; 1997.
18. Reitan RM, Davidson LA. Clinical Neuropsychology: Current Status and Applications. New York, NY: John Wiley & Sons; 1974.
19. Smith A. Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services; 1973.
20. Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test. New York, NY: The Psychological Corporation; 2000.
21. Golden CJ. Stroop Color and Word Test: A Manual for Clinical and Experimental Uses. Wood Dale, IL: Stoelting Company; 1978.
22. Heaton RK, Chelune GJ, Talley JL, et al. Wisconsin Card Sorting Test (WCST) Manual Revised and Expanded. Odessa, FL: Psychological Assessment Resources; 1993.
23. Matthews CG, Klove H. Instruction Manual for the Adult Neuropsychology Test Battery. Madison, WI: University of Wisconsin Medical School; 1964.
24. Benton AL, Hamsher K, Sivan AB. Multilingual Aphasia Examination. Iowa City, IA: AJA Associates; 1994.
25. Gladsjo JA, Schuman CC, Evans JD, et al. Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment. 1999;6:147-178.
26. Reitan RM. Finger Tapping Test. Tucson, AZ: Reitan Neuropsychology Laboratory; 1979.
27. Reitan RM, Wolfson D. Grooved Pegboard. The Halstead-Reitan Extended Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press; 1985.
28. Chapman RL. The MacQuarrie test for mechanical ability. Psychometrika. 1948;13:175-179.
29. Wechsler D. Escala de Inteligencia Wechsler para Adultos (WAIS-III). 3rd ed. Madrid, Spain: TEA Ediciones; 1999.
30. Periáñez JA, Ríos-Lago M, Rodríguez- Sánchez JM, et al. Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing: sample comparisons and normative data. Arch Clin Neuropsychol. 2007;22:433-477.
31. Smith A. Test de Símbolos y Dígitos (SDMT). Madrid, Spain: TEA Ediciones; 2002.
32. Golden CH. Stroop. Test de Colores y Palabras. Madrid, Spain: TEA Ediciones; 2001.
33. Culbertson WC, Zillmer EA. Tower of London-drexel University (TOLDX). Toronto, Canada: Multi-Health Systems Inc; 2001.
34. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol. 1999;14:167-177.
35. Wpspublish.com. Electronic Tapping Test. Los Angeles, CA: Western Psychological Services; 2001.
36. MacQuarrie TW. Test de Habilidades Mecánicas. Subtest de Marcado. Madrid, Spain: TEA Ediciones; 2003.
37. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24: 1243-1250.
38. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and posthighly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol. 2004;10:350-357.
39. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265-273.
40. Wojna V, Skolasky RL, Hechavarría R, et al. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol. 2006; 12:356-364.
41. Arendt G, Nolting T, Frisch C, et al. Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease. J Neurovirol. 2007;13:225-232.
42. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087-2096.
43. Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol. 2004;18:234-248.
44. Ellis RJ, Evans SR, Clifford DB, et al. Clinical validation of the Neuro-Screen. J Neurovirol. 2005;11:503-511.
45. Power C, Selnes OA, Grim JA, et al. HIV Dementia Scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8: 273-278.
46. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19: 1367-1374.
47. Smith CA, van Gorp WG, Ryan ER, et al. Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale. J Acquir Immune Defic Syndr. 2003;33:116-118.
48. Bottiggi KA, Chang JJ, Schmitt FA, et al. The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci. 2007;260:11-15.
49. Waldrop-Valverde D, Nehra R, Sharma S, et al. Education effects on the International HIV Dementia Scale. J Neurovirol. 2010;16:264-267.
50. Sakamoto M, Marcotte TD, Umlauf A, et al. Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER cohort. J Acquir Immune Defic Syndr. 2013; 62:36-42.
51. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-699.
52. Koski L, Brouillette MJ, Lalonde R, et al. Computerized testing augments pencil-and-paper tasks in measuring HIV-associated mild cognitive impairment. HIV Med. 2011;12:472-480.
53. Overton ET, Azad TD, Parker N, et al. The Alzheimer's disease-8 and Montreal Cognitive Assessment as screening tools for neurocognitive impairment in HIV-infected persons. J Neurovirol. 2013;19:109-116.
54. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17:3-16.
55. Overton ET, Kauwe JS, Paul R, et al. Performances on the CogState and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav. 2011;15:1902-1909.
56. Moore DJ, Roediger MJ, Eberly LE, et al. Identification of an abbreviated test battery for detection of HIV-associated neurocognitive impairment in an early-managed HIV-infected cohort. PLoS One. 2012;7:e47310.
57. Heaton RK, Temkin N, Dikmen S, et al. Detecting change: a comparison of three neuropsychological methods, using normal and clinical samples. Arch Clin Neuropsychol. 2001;16:75-91.
58. Levine AJ, Hinkin CH, Miller EN, et al. The generalizability of neurocognitive test/retest data derived from a nonclinical sample for detecting change among two HIV+ cohorts. J Clin Exp Neuropsychol. 2007;29: 669-678.
59. Cysique LA, Franklin D Jr, Abramson I, et al CHARTER Group; HNRC Group. Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol. 2011;33:505-522.